PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28540312-4	2017	We present a case in which a patient successfully underwent a 3-month course of rivaroxaban in addition to his dual antiplatelet regimen of aspirin and ticagrelor for his STE-ACS and LV thrombus with resultant complete dissolution.	Rivaroxaban	80-91	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	175-178	
25440788-7	2014	Finally, the combination of aspirin, clopidogrel, and low-dose rivaroxaban has recently been approved by the European Medicines Agency (but not the Food and Drug Administration) for secondary prevention after ACS.	Rivaroxaban	63-74	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	209-212	
24022544-5	2013	Dual pathway regimens that combine antiplatelets (aspirin and a thienopyridine), along with an anticoagulant such as rivaroxaban may prove to be a therapeutic option in patients with ACS.	Rivaroxaban	117-128	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	183-186	
33305222-10	2020	Conclusions: This study provides a first look at how the introduction of rivaroxaban 2.5 mg might be integrated into the clinical management of ACS patients beyond the first year in Canada.	Rivaroxaban	73-84	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	144-147